scispace - formally typeset
S

Saumen Mandal

Researcher at University of Manitoba

Publications -  33
Citations -  185

Saumen Mandal is an academic researcher from University of Manitoba. The author has contributed to research in topics: Estimator & Optimal design. The author has an hindex of 7, co-authored 30 publications receiving 169 citations.

Papers
More filters
Book ChapterDOI

Optimal Adaptive Designs in Phase III Clinical Trials for Continuous Responses with Covariates

TL;DR: In this article, an optimal adaptive allocation for two treatments having some continuous responses was proposed for phase III clinical trials involving two binary responses having binary responses, but no covariate, where covariates were allowed in the model.
Journal ArticleDOI

Construction of optimal designs using a clustering approach

TL;DR: The idea is that, at an appropriate iterate p ( r ) , the single distribution should be replaced by conditional distributions within clusters and a marginal distribution across the clusters, which is formulated for a general regression model and then is explored through several regression models.
Journal ArticleDOI

Two classes of multiplicative algorithms for constructing optimizing distributions

TL;DR: A class of multiplicative algorithms, indexed by a function f(.), which depends on the derivatives of the criterion function, is used to construct approximate optimizing distributions p j by maximizing a criterion function subject to the basic constraints on p"j of nonnegativity and summation to unity.
Journal ArticleDOI

Constructing optimal designs with constraints

TL;DR: A class of multiplicative algorithms indexed by a function f (·) is used, shown to satisfy the basic constraints on the design weights of nonnegativity and summation to unity.
Journal ArticleDOI

Multi-treatment optimal response-adaptive designs for phase III clinical trials

TL;DR: In this paper, a generalized framework is proposed to derive multi-treatment optimal response-adaptive designs for phase-III clinical trials, and a detailed performance study is provided for three treatment trials minimising failures.